Analysis of the GeneXpert System on the International Multicentre ICORG 08-02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML)

M.E. O'Dwyer, R. Swords, F. Giles, Mary Frances McMullin, P.D. Le Coutre, A. Nagler, S. Langabeer, M. Wieczorkowska, C. McDowell, K. Egan, B. Moulton, E. Conneally

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)1612-1613
Number of pages2
JournalBlood
Volume118
Publication statusPublished - Dec 2011

Cite this

O'Dwyer, M. E., Swords, R., Giles, F., McMullin, M. F., Le Coutre, P. D., Nagler, A., Langabeer, S., Wieczorkowska, M., McDowell, C., Egan, K., Moulton, B., & Conneally, E. (2011). Analysis of the GeneXpert System on the International Multicentre ICORG 08-02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML). Blood, 118, 1612-1613.